Astellas Pharma Inc

YPHA

Company Profile

  • Business description

    Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

  • Contact

    2-5-1 Nihonbashi-Honcho
    Chuo-ku
    Tokyo103-8411
    JPN

    T: +81 332443000

    https://www.astellas.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 March 2026

    Employees

    13,643

Stocks News & Analysis

stocks

Undervalued Aussie e-commerce winner

Shares attractive due to near term profit margin increase and structural growth.
stocks

Our view on oil prices after Maduro is deposed

We’ve revisited our oil price assumptions after the news from Venezuela.
stocks

Nvidia: Full steam ahead with an impressive array of announcements at CES 2026

Our view of Nvidia at the current share price.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,018.0021.50-0.24%
CAC 408,226.5210.91-0.13%
DAX 4025,038.20146.000.59%
Dow JONES (US)49,462.08484.900.99%
FTSE 10010,055.0267.71-0.67%
HKSE26,458.95251.50-0.94%
NASDAQ23,547.17151.350.65%
Nikkei 22551,961.98556.10-1.06%
NZX 50 Index13,715.0251.440.38%
S&P 5006,944.8242.770.62%
S&P/ASX 2008,695.6027.90-0.32%
SSE Composite Index4,085.772.100.05%

Market Movers